3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, bone fragility has emerged as a side effect in some but not in all human studies. Because use of SGLT2 inhibitors in humans affects mineral metabolism, we investigated the long‐term effects of genetic loss of Sglt2 function on bone and mineral metabolism in mice. Slc5a2 nonsense mutation in Sweet Pee (SP) mice results in total loss of Sglt2 function. We collected urine, serum, and bone samples from 15‐week‐old and 25‐week‐old wild‐type (WT) and SP mice fasted from food overnight. We measured parameters of renal function and mineral metabolism and we assessed bone growth, microarchitecture, and mineralization. As expected, 15‐week‐old and 25‐week‐old SP mice showed increased glucosuria, and normal kidney function compared to age‐matched WT mice. At 15 weeks, SP mice did not show alterations in mineral metabolism parameters. At 25 weeks, SP mice showed reduced fasting 24‐hour urinary calcium excretion and increased fractional excretion of phosphate, but normal serum calcium and phosphate, parathyroid hormone (PTH), vitamin D (1,25(OH) 2D), and fibroblast growth factor (FGF23) levels. At 25 weeks, but not at 15 weeks, SP mice showed reduced body weight compared to WT. This was associated with reduced femur length at 25 weeks, suggesting impaired skeletal growth. SP mice did not show trabecular or cortical bone microarchitectural modifications but showed reduced cortical bone mineral density compared to WT mice at 25 weeks. These results suggest that loss of Sglt2 function in mice in the absence of T2DM does not alter regulatory hormones FGF23, PTH, and 1,25(OH) 2D, but may contribute to bone fragility over the long term. Future studies are required to determine how loss of Sglt2 function impacts bone fragility in T2DM. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

          The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

            The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

              Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.
                Bookmark

                Author and article information

                Contributors
                aline.martin@northwestern.edu , tamara.isakova@northwestern.edu
                aline.martin@northwestern.edu
                Journal
                JBMR Plus
                JBMR Plus
                10.1002/(ISSN)2473-4039
                JBM4
                JBMR Plus
                John Wiley & Sons, Inc. (Hoboken, USA )
                2473-4039
                06 July 2021
                August 2021
                : 5
                : 8 ( doiID: 10.1002/jbm4.v5.8 )
                : e10526
                Affiliations
                [ 1 ] Division of Nephrology and Hypertension, Feinberg School of Medicine Northwestern University Chicago IL USA
                [ 2 ] Center for Translational Metabolism and Health, Institute for Public Health and Medicine Northwestern University Chicago IL USA
                [ 3 ] Feinberg Cardiovascular and Renal Research Institute Northwestern University Chicago IL USA
                Author notes
                [*] [* ] Address correspondence to: Tamara Isakova, MD 633 N. St. Clair St., Suite 18‐089, Chicago, IL 60611, USA and Aline Martin, PhD, 320 E Superior St, Searle 10th floor, Chicago, IL, USA. E‐mail: tamara.isakova@ 123456northwestern.edu (Isakova); aline.martin@ 123456northwestern.edu (Martin)

                Author information
                https://orcid.org/0000-0002-0144-9294
                Article
                JBM410526
                10.1002/jbm4.10526
                8328801
                34368611
                cb34921c-0013-49b6-8e29-eb6686e438f6
                © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 20 May 2021
                : 14 December 2020
                : 16 June 2021
                Page count
                Figures: 5, Tables: 3, Pages: 8, Words: 6576
                Funding
                Funded by: American Society of Nephrology , doi 10.13039/100001463;
                Award ID: Donal E. Wesson Research Fellowship Award
                Funded by: National Heart, Lung, and Blood Institute , doi 10.13039/100000050;
                Award ID: K24HL150235
                Funded by: National Institute of Diabetes and Digestive and Kidney Diseases , doi 10.13039/100000062;
                Award ID: P30DK114857
                Award ID: R01DK101730
                Award ID: R01DK114158
                Award ID: T32DK007169
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                August 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.4 mode:remove_FC converted:02.08.2021

                bone,calcium,glycosuria,phosphate,sglt2
                bone, calcium, glycosuria, phosphate, sglt2

                Comments

                Comment on this article